Noninferiority of inhaled epoprostenol to inhaled nitric oxide for the treatment of ARDS

Annals of Pharmacotherapy

Volumn 49, Issue 10, 2015, Pages 1105-1112

  Ammar, Mahmoud A ^a   Bauer, Seth R ^a   Bass, Stephanie N ^a   Sasidhar, Madhu ^a   Mullin, Rory ^a   Lam, Simon W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

ARDS; Epoprostenol; Hypoxemia; Nitric oxide; Pulmonary vasodilator

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN; VASODILATOR AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALGORITHM; ARTERIAL OXYGEN TENSION; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; COHORT ANALYSIS; DRUG SAFETY; FEMALE; HUMAN; HYPOXEMIA; INTENSIVE CARE UNIT; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; VENTILATED PATIENT; ANOXIA; COMPARATIVE STUDY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT; TIME;

ADMINISTRATION, INHALATION; AGED; ANOXIA; EPOPROSTENOL; FEMALE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PROPENSITY SCORE; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; TIME FACTORS; VASODILATOR AGENTS; VENTILATOR WEANING;

EID: 84952773902     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015595642     Document Type: Article

References (30)

1. Bernard GR, Artigas A, Brigham KL, et al. Report of the American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes and clinical trial coordination. The Consensus Committee. Intensive Care Med. 1994;20:225-232. doi:10. 1007/BF01704707.
2. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008;133:1120-1127. doi:10. 1378/chest. 07-2134.
3. Dushianthan A, Grocott MP, Postle AD, Cusack R. Acute respiratory distress syndrome and acute lung injury. Postgrad Med J. 2011;87:612-622. doi:10. 1136/pgmj. 2011. 118398.
4. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med. 2000;342:1334-1349. doi:10. 1056/ NEJM200005043421806.
5. Stapleton RD, Wang BM, Hudson LD, Rubenfeld GD, Caldwell ES, Steinberg KP. Causes and timing of death in patients with ARDS. Chest. 2005;128:525-532. doi:10. 1378/chest. 128. 2. 525.
6. Walmrath D, Schneider T, Schermuly R, Olschewski H, Grimminger F, Seeger W. Direct comparison if inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:991-996. doi:10. 1164/ajrccm. 153. 3. 8630585.
7. Puri N, Dellinger RP. Inhaled nitric oxide and inhaled prostacyclin in acute respiratory distress syndrome: what is the evidence? Crit Care Clin. 2011;27:561-587. doi:10. 1016/j. ccc. 2011. 05. 001.
8. Buckley MS, Feldman JP. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy. 2010;30:728-740. doi:10. 1592/phco. 30. 7. 728.
9. Sokol J, Jacobs SE, Bohn D. Inhaled nitric oxide for acute hypoxic respiratory failure in children and adults: a metaanalysis. Anesth Analg. 2003;97:989-998. doi:10. 1213/01. ANE. 0000078819. 48523. 26.
10. Dzierba AL, Abel EE, Buckley MS, Lat I. A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome. Pharmacotherapy. 2014;34:279-290. doi:10. 1002/phar. 1365.
11. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307:2526-2533. doi:10. 1001/jama. 2012. 5669.
12. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology. 2002;96:576-582. doi:10. 1097/00000542-200203000-00011.
13. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med. 2006;354:2564-2575. doi:10. 1056/NEJMoa062200.
14. Schoenfeld DA, Bernard GR, Network A. Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med. 2002;30:1772-1777. doi:10. 1097/00003246- 200208000-00016.
15. Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med. 1998;157(5 pt 1):1483-1488. doi:10. 1164/ajrccm. 157. 5. 9707090.
16. Rosenbaum PR, Rubin DB. Constructing a controlgroup using multivariate matched sampling methods that incorporate the propensity score. Am Stat. 1985;39:33-38. doi:10. 2307/2683903.
17. Torbic H, Szumita PM, Anger KE, Nuccio P, LaGambina S, Weinhouse G. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care. 2013;28:844-848. doi:10. 1016/j. jcrc. 2013. 03. 006.
18. Adhikari NK, Dellinger RP, Lundin S, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: systematic review and meta-analysis. Crit Care Med. 2014;42:404-412. doi:10. 1097/CCM. 0b013e3182a27909.
19. Beloucif S, Payen D. A European survey of the use of inhaled nitric oxide in the ICU. Working Group on Inhaled NO in the ICU of the European Society of Intensive Care Medicine. Intensive Care Med. 1998;24:864-877. doi:10. 1007/ s001340050679.
20. Meade MO, Jacka MJ, Cook DJ, Dodek P, Griffith L, Guyatt GH. Survey of interventions for the prevention and treatment of acute respiratory distress syndrome. Crit Care Med. 2004;32:946-954. doi:10. 1097/01. CCM. 0000120056. 76356. AD.
21. Van Heerden PV, Blythe D, Webb SA. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS-a pilot study. Anaesth Intensive Care. 1996;24:564-568.
22. Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6 pt 1):1671-1677. doi:10. 1164/ajrccm. 154. 6. 8970353.
23. Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit Care Med. 1998;26:15-23. doi:10. 1097/00003246-199801000-00011.
24. Taylor RW, Zimmerman JL, Dellinger RP, et al. Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial. JAMA. 2004;291:1603-1609. doi:10. 1001/jama. 291. 13. 1603.
25. Slutsky AS. Neuromuscular blocking agents in ARDS. N Engl J Med. 2010;363:1176-1180. doi:10. 1056/NEJMe1007136.
26. Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363:1107-1116. doi:10. 1056/NEJMoa 1005372.
27. Gerlach H, Keh D, Semmerow A, et al. Dose-response characteristics during long-term inhalation of nitric oxide in patients with severe acute respiratory distress syndrome: a prospective, randomized, controlled study. Am J Respir Crit Care Med. 2003;167:1008-1015. doi:10. 1164/ rccm. 2108121.
28. Guerin C, Reignier J, Richard JC, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368:2159-2168. doi:10. 1056/NEJMoa1214103.
29. Albert RK, Keniston A, Baboi L, Ayzac L, Guerin C. Prone position-induced improvement in gas exchange does not predict improved survival in the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2014;189:494-496. doi:10. 1164/rccm. 201311-2056LE.
30. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41:580-637. doi:10. 1097/CCM. 0b013e31827e83af.